Larry discusses the heightened risks in emerging markets, particularly in light of recent geopolitical events. He expresses skepticism about private investments in these regions, favoring public investments in developed markets, especially the US. Highlighting the inefficiencies in the biotech sector, he shares a more optimistic outlook for potential gains there, suggesting it may offer both alpha and beta opportunities.
